Evidence map›Paper›PMID 36387183›Full record

ArticleFrontiers in oncology2022

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment.

Mingyu Wan, Yongfeng Ding, Chenyu Mao, Xiaolu Ma, Ning Li, Cheng Xiao, Jiong Qian, Haiping Jiang, Yulong Zheng, Luntao Wu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 9 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 9 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mingyu WanDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Yongfeng DingDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Chenyu MaoDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Xiaolu MaDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Ning LiDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Cheng XiaoDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Jiong QianDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Haiping JiangDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Yulong ZhengDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Luntao WuDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Lisong TengDepartment of Surgical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Nong XuDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The emergence of immune checkpoint inhibitors has changed the landscape of first-line treatment of patients with advanced gastric cancer. Currently, the prognostic significance of inflammatory markers in first-line immunotherapy combined with chemotherapy for gastric cancer is currently unclear. This study aimed to identify inflammatory markers with potential to predict treatment outcome in advanced gastric cancer patients receiving immunotherapy combined with chemotherapy. Methods: This retrospective study enrolled untreated advanced or metastatic gastric or gastro-esophageal junction cancer patients from 5 clinical trials (the clinical trial cohort) and the real world (the real-word cohort). Inflammatory markers included in the analysis included neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), and derived neutrophil-to-lymphocyte ratio (dNLR). Receiver operating characteristic (ROC) curves were constructed to identify optimal cut-off values. The prognostic potential of the markers was determined using Kaplan-Meier analysis, univariate and multivariate Cox-regression analyses in the clinical trial cohort and the findings were validated in the real-world cohort. Results: In the clinical trial cohort (n=45), MLR, PLR and SII were associated with PFS but not OS (All P<0.05), while dNLR was not correlated with PFS or OS. Only NLR was associated with PFS and OS and identified as an independent prognostic predictor in the univariate and multivariate analyses. The prognostic value of NLR was validated in the real-world cohort (n=55). Conclusions: NLR was a strong predictor of PFS and OS in patients with advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy. Further prospective studies are required to validate our results.

Indexed as

gastric cancerimmune checkpoint inhibitorinflammatory markersneutrophil-to-lymphocyte ratioprognosis

Identifiers

PMID36387183
PMCPMC9650180
OpenAlexW4307703731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.